Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Keywords

BiologyCancerOncologyImmunotherapyInternal medicineOverall survivalSurvival analysisSomatic cellCancer researchMedicineGeneticsGene

Affiliated Institutions

Related Publications

The Immune Landscape of Cancer

Vésteinn Thórsson , David L. Gibbs , Scott D. Brown +97 more

We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identi...

2018 Immunity 5827 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Peng Jiang , Shengqing Gu , Deng Pan +12 more

Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we ...

2018 Nature Medicine 5230 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Publication Info

Year: 2019
Type: article
Volume: 51
Issue: 2
Pages: 202-206
Citations: 4163
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

4163

OpenAlex

Cite This

APA Style

                            
                                
                                    Robert M. Samstein, 
                                
                                    Chung‐Han Lee, 
                                
                                    Alexander N. Shoushtari
                                
                                et al.
                            
                            (2019). 
                            Tumor mutational load predicts survival after immunotherapy across multiple cancer types. 
                            Nature Genetics
                            , 51
                            (2)
                            , 202-206.
                            https://doi.org/10.1038/s41588-018-0312-8
                        

Identifiers

DOI: 10.1038/s41588-018-0312-8